Title :

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment

Author(s) :

Fenwarth, Laurene [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Fournier, Elise [Auteur]
Hôpital Claude Huriez [Lille]
Cheok, Meyling [Auteur]
Institut pour la recherche sur le cancer de Lille [Lille] [IRCL]
Boyer, Thomas [Auteur]
HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 [HEMATIM]
Gonzales, Fanny [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Castaigne, Sylvie [Auteur]
Boissel, Nicolas [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Lambert, Juliette [Auteur]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Dombret, Herve [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Preudhomme, Claude [Auteur]
Service d'Hématologie Cellulaire [Lille]
Duployez, Nicolas [Auteur]
Hôpital Claude Huriez [Lille]

Journal title :

International Journal of Molecular Sciences

Publisher :

MDPI

Publication date :

2020

ISSN :

1661-6596

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Gemtuzumab ozogamicin (GO, Mylotarg(R)) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved ...
Show more >Gemtuzumab ozogamicin (GO, Mylotarg(R)) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved outcomes in CD33-positive AML patients across phase I to III clinical trials, led to the Food and Drug Administration (FDA) approval on 1 September 2017 in CD33-positive AML patients aged 2 years and older. Discrepancies in GO recipients outcome have raised significant efforts to characterize biomarkers predictive of GO response and have refined the subset of patients that may strongly benefit from GO. Among them, CD33 expression levels, favorable cytogenetics (t(8;21), inv(16)/t(16;16), t(15;17)) and molecular alterations, such asNPM1,FLT3-internal tandem duplications and other signaling mutations, represent well-known candidates. Additionally, in depth analyses including minimal residual disease monitoring, stemness expression (LSC17 score), mutations or single nucleotide polymorphisms in GO pathway genes (CD33,ABCB1) and molecular-derived scores, such as the recently set up CD33_PGx6_Score, represent promising markers to enhance GO response prediction and improve patient management.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL